Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

TP53 mutation promotes diffuse large B-cell lymphoma progression via mediating lactylation of ATP5E at Lys44

Linquan Zhan, Chenyang Jiang, Tiange Lu, Hua Wang, Xiangxiang Zhou

Blood (2025) 146 (Supplement 1): 5037.

https://doi.org/10.1182/blood-2025-5037

Published: 2025

Journal Articles

Exploring the disease impact of plasma metabolites on marginal zone lymphoma based on mendelian randomization

Yupiao Feng, Xinting Hu, Yutang Li, Hua Wang, Kang Lu, Xiangxiang Zhou

Blood (2025) 146 (Supplement 1): 7122.

https://doi.org/10.1182/blood-2025-7122

Published: 2025

Journal Articles

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

Zhifeng Li, Hua Wang, Zhijuan Lin, Li Yu, Shaojie Wu, Na Qin, Jie Zha, Long Liu, Manman Deng, Bing Xu

Blood (2025) 146 (Supplement 1): 3580.

https://doi.org/10.1182/blood-2025-3580

Published: 2025

Journal Articles

Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial

Xiaoqin Chen, Yun Wang, Zhijian Liang, Weida Wang, Hua Wang, Bingyi Wu, Yang Liang, Zhongjun Xia

Blood (2025) 146 (Supplement 1): 5829.

https://doi.org/10.1182/blood-2025-5829

Published: 2025

Journal Articles

Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma

Zhijuan Lin, Long Liu, Manman Deng, Xingxing Yu, Yan Hong, Hua Wang, Keshu Zhou, Shaojie Wu, Ting-Bo Liu, Na Qin, Rui Su, Zhifeng Li, Bing Xu

Blood (2025) 146 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2025-1818

Published: 2025

Journal Articles

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

Blood (2025) 146 (Supplement 1): 7546.

https://doi.org/10.1182/blood-2025-7546

Published: 2025

Journal Articles

First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models

Jun Wei, Richard Jones, Isere Kuiatse, Hua Wang, Robert Orlowski

Blood (2025) 146 (Supplement 1): 388.

https://doi.org/10.1182/blood-2025-388

Published: 2025

Journal Articles

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

Blood (2025) 145 (22): 2614–2629.

https://doi.org/10.1182/blood.2024024781

Published: 2025

Includes: Supplemental data

Journal Articles

A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Shaojie Wu, Junru Du, Jie Ma, Li Huang, Zhiqiang Peng, Yiwen Ling, Xiaofang Deng, Weijian Zhu, Hongliang Li, Hua Wang, Yuhua Li

Blood (2024) 144 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2024-200667

Published: 2024

Journal Articles

Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma

Wei Tan, Minghao Dang, Upasana Ray, Luz Yurany Moreno Rueda, Maria Jose Acevedo-Calado, Hua Wang, Jun Wei, Li Qin, Isere Kuiatse, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 4640.

https://doi.org/10.1182/blood-2024-207917

Published: 2024

Journal Articles

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study

Dong Liang, Demei Feng, Qiaoli Wang, Shenrui Bai, Min Zeng, Bo Lu, Xiaoqing Li, Zhiqiang Sun, Jianyun Li, Huanhuan Zhou, Jialu Zhang, Xiaoqin Chen, Zhongjun Xia, Yang Liang, Hua Wang

Blood (2024) 144 (Supplement 1): 7064.

https://doi.org/10.1182/blood-2024-204519

Published: 2024

Journal Articles

Safety and Efficacy of Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma: A Multi-Center, Single-Arm, Phase Ib/II Trial

Xiaoqin Chen, Yun Wang, Weida Wang, Hua Wang, Bingyi Wu, Yang Liang, Zhongjun Xia

Blood (2024) 144 (Supplement 1): 7025.

https://doi.org/10.1182/blood-2024-204564

Published: 2024

Journal Articles

Sustained FVIII Expression with a Tolerable, Titratable, Fully Non-Viral Gene Therapy for Hemophilia a

Johannes Schwerk, Mauricio Barajas-Mora, Hua Wang, Brian Truong, Michael Bennett, Nicholas Cam, James Clancey, Alicia Davis, Khal Hajj, Bonnie Jacques, Johnnatan Tamayo, James Yen, Joshua Rychak, Blair Madison

Blood (2024) 144 (Supplement 1): 7462.

https://doi.org/10.1182/blood-2024-211223

Published: 2024

Journal Articles

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Fujing Zhang, Wei Wang, Hua Wang, Wei Wang, Aijun Liu, Weiwei Tian, Xiaoqi Qin, Zhongjun Xia, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2024-209342

Published: 2024

Journal Articles

Efficacy and Safety of Carfilzomib-Based Regimens in a Real-World Clinical Practice: Insights from China

Dong Liang, Demei Feng, Yang Liang, Hua Wang

Blood (2024) 144 (Supplement 1): 7875.

https://doi.org/10.1182/blood-2024-203304

Published: 2024

Journal Articles

A Retrospective Analysis of Orelabrutinib-Containing Regimen for Marginal Zone Lymphoma

Hua Wang, Yang Liang, Dong Liang, Demei Feng

Blood (2024) 144 (Supplement 1): 6332.

https://doi.org/10.1182/blood-2024-203319

Published: 2024

Journal Articles

Fatty Acid Metabolism Shapes Immune Function and PI3K Inhibitor Sensitivity in Chronic Lymphocytic Leukemia

Yang Zhang, Jun Ma, Hua Wang, Pan Gao, Xin Wang, Ya Zhang

Blood (2024) 144 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2024-208098

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine As Induction Therapy for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

Yun Wang, Weida Wang, Jingbo Xu, Ji Ma, Hua Wang, Bingyi Wu, Yuanbin Song, Weiran Lv, Lezong Chen, Jun Ma, Tiejun Gong, Yang Liang

Blood (2024) 144 (Supplement 1): 6074.

https://doi.org/10.1182/blood-2024-209055

Published: 2024

Journal Articles

Treatment Outcomes of Zanubrutinib-Based Regimen in Newly Diagnosed Patients with MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Real-World Study

Bo Lu, Jihao Zhou, Fangjie Liu, Jingwei Zhang, Hua Wang

Blood (2024) 144 (Supplement 1): 6517.

https://doi.org/10.1182/blood-2024-200733

Published: 2024

Journal Articles

PRMT1 Promotes Chronic Lymphocytic Leukemia Progression Via Modulating Methylation of MAST1

Zheng Tian, Ya Zhang, Hua Wang, Liyan Lu, Xin Wang

Blood (2023) 142 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2023-183058

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TP53 mutation promotes diffuse large B-cell lymphoma progression via mediating lactylation of ATP5E at Lys44

Exploring the disease impact of plasma metabolites on marginal zone lymphoma based on mendelian randomization

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial

Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study

Safety and Efficacy of Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma: A Multi-Center, Single-Arm, Phase Ib/II Trial

Sustained FVIII Expression with a Tolerable, Titratable, Fully Non-Viral Gene Therapy for Hemophilia a

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Efficacy and Safety of Carfilzomib-Based Regimens in a Real-World Clinical Practice: Insights from China

A Retrospective Analysis of Orelabrutinib-Containing Regimen for Marginal Zone Lymphoma

Fatty Acid Metabolism Shapes Immune Function and PI3K Inhibitor Sensitivity in Chronic Lymphocytic Leukemia

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine As Induction Therapy for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

Treatment Outcomes of Zanubrutinib-Based Regimen in Newly Diagnosed Patients with MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Real-World Study

PRMT1 Promotes Chronic Lymphocytic Leukemia Progression Via Modulating Methylation of MAST1

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only